France Leads Europe In Reimbursing Truvada For HIV Prophylaxis
This article was originally published in Scrip
Executive Summary
Gilead Sciences' HIV drug Truvada is now being reimbursed in France for pre-exposure prophylaxis (PrEP) under a "temporary use recommendation" (RTU) that came into effect on Jan. 4. This is understood to be the first European country where Truvada can be officially prescribed and reimbursed for PrEP, an indication for which it has not yet received an EU marketing authorization.
You may also be interested in...
Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain
The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.
Hepatitis C And PrEP Bring More Funding Headaches For NHS England
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.